Bladder Cancer

Bladder Cancer

Patients with bladder cancer derived an overall survival benefit from the use of adjuvant chemotherapy compared with observation.

A urine test (CellDetect) was able to detect disease recurrence in bladder cancer patients, with a reported sensitivity of 84.4% and specificity of 82.7%.

While observation may be appropriate for select cases where prognosis is poor, rates of non-treatment are unacceptably high in muscle-invasive bladder cancer.

Long-term survival rates of patients after laparoscopic surgery for bladder cancer are similar to rates achieved with standard open surgery.

An extremely large database study across more than one million people found no increased risk of bladder cancer with the diabetes drug pioglitazone.

A large phase I study showed that the PD-L1 antibody known as MPDL3280A has promising activity in patients with urothelial bladder cancer.

Cancer survivors are at an increased risk for developing a second smoking-associated cancer if they smoked cigarettes prior to their first cancer diagnosis.


Subscribe to Bladder Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.